Clinical trial reportClinical pharmacology and therapeuticsPublished
Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology Results
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Clinical pharmacology and therapeutics
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Multiple Myeloma; Antibodies, Bispecific; Dose-Response Relationship, Drug; Half-Life; Adult; Aged; Middle Aged; Female; Male; Antineoplastic Agents, Immunological
- PubMed ID
- 40704375
- PubMed Central ID
- PMC12439005
- Open access
- Yes, open
- Added to directory
- Source checked